Home Prescription Drugs Tags

View the Latest: Prescription Drugs

Filter

List Grid

571 - 580 of 792 Results

  • Primers on Key Health Care Topics and Programs

    Issue Brief

    The Kaiser Family Foundation maintains a number of primers providing overviews of key health care programs and issues. Written by Foundation staff, each primer provides key data and information that helps illustrate the topic and its relevance for the nation's health care system. Medicaid: A Primer Medicare: A Primer The Uninsured: A Primer Health Care Costs: A Primer How Private Health Coverage Works: A Primer Mental Health Financing in the United States: A Primer The…

  • Medicare Part D 2010 Data Spotlight: Coverage of Top Brand-Name and Specialty Drugs

    Issue Brief

    This Part D Data Spotlight documents the wide variations across the private stand-alone drug plans with respect to coverage of drugs, what enrollees pay for those drugs, and restrictions and limitations placed on their use. These variations have potentially significant implications for beneficiaries’ access to medications and out-of-pocket costs. The spotlight is one in a series analyzing key aspects of the Medicare Part D drug plans that will be available to beneficiaries in 2010. The…

  • Medicare Part D 2011 Data Spotlight: The Coverage Gap

    Report

    This data spotlight examines the availability of gap coverage in the private Medicare Part D drug plans offered to beneficiaries in 2011, the first year of the phase-out of the gap, as required under the 2010 health reform law. The changes for 2011 include a 50 percent discount on brand-name drugs purchased during the gap in coverage, reducing an enrollee’s potential out-of-pocket costs in the gap from about $3,600 to $1,800. The analysis was conducted…

  • Medicare Part D Spending Trends: Understanding Key Drivers and the Role of Competition

    Issue Brief

    This brief commissioned by the Foundation examines factors that contributed to Medicare's lower-than-expected spending on prescription drugs under the Medicare Part D drug benefit that started in 2006. Since its launch, Medicare has spent about 30 percent less on Part D benefits than the Congressional Budget Office originally projected. Some cite the program's design, with private plans competing for enrollment, as the driving factor in lower spending; others point to factors in the overall market…

  • Medicaid and Prescription Drugs: An Overview

    Report

    This background paper discusses the coverage of prescription drugs through the Medicaid program. Some of the issues addressed include who is eligible to receive drugs, how drug coverage is paid for, and how much money states spend on drugs. Background Paper

  • Prescription Drug Trends:  A Chartbook Update

    Report

    This November 2001 Chartbook updates data from last year's chartbook, including information about prescription drug coverage, expenditures and prices, utilization, drug promotion, and the pharmaceutical industry.

  • Kaiser Family Foundation/Harvard School of Public Health National Survey of the Public’s Views on Medicare- Chartpack

    Report

    Kaiser Family Foundation/Harvard School of Public Health National Survey of the Public's Views on Medicare A national survey by the Kaiser Family Foundation and the Harvard School of Public Health examines the public's attitudes and opinions on issues related to the Medicare reform and prescription drug debate. The survey also takes a separate look at the differing views of younger and older Americans on this topic. Chartpack (.pdf)

  • The Effects of Formularies and Other Cost Management Tools on Access to Medications:  An Analysis of the MMA and the Final Rule

    Issue Brief

    This report examines the formulary and cost management provisions of the final Medicare regulations implementing the new Medicare Part D drug benefit that was passed as part of the Medicare Modernization Act of 2003, and their implications for people with Medicare who enroll in new drug plans and their access to medications. It was prepared for the Foundation by Jack Hoadley, Ph.D., of the Health Policy Institute at Georgetown University. Issue Brief (.pdf)

  • Unintended Consequences: The Potential Impact of Medicare Part D on Dual Eligibles with Disabilities in Medicaid Work Incentive Programs

    Report

    Individuals with disabilities who are eligible for both Medicare and Medicaid must also shift to a Medicare prescription drug benefit in 2006. This report analyzes how younger dual eligibles in Kansas enrolled in work incentive programs differ than other Medicare enrollees in the types of drugs they use and how much drug spending they have to better assess the impact of the Medicare drug benefit on this population. Report (.pdf)